{"id":"https://openalex.org/W2531748673","doi":"https://doi.org/10.1212/wnl.86.16_supplement.p2.336","title":"The Effects of Sublingual Apomorphine (APL-130277) by Disease Severity on the Acute Management of OFF Episodes in Parkinson\u2019s Disease (P2.336)","display_name":"The Effects of Sublingual Apomorphine (APL-130277) by Disease Severity on the Acute Management of OFF Episodes in Parkinson\u2019s Disease (P2.336)","alternate_titles":[],"publication_year":2016,"publication_date":"2016-04-05","ids":{"openalex":"https://openalex.org/W2531748673","doi":"https://doi.org/10.1212/wnl.86.16_supplement.p2.336","mag":"2531748673"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.86.16_supplement.p2.336","doi":"https://doi.org/10.1212/wnl.86.16_supplement.p2.336","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.86.16_supplement.p2.336","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2531748673"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067565944","display_name":"Holly A. Shill","orcid":"https://orcid.org/0000-0003-1284-5038","observed_orcids":["https://orcid.org/0000-0003-1284-5038"]},"institutions":[{"id":"https://openalex.org/I1324766304","display_name":"Barrow Neurological Institute","ror":"https://ror.org/01fwrsq33","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324766304","https://openalex.org/I1325481341","https://openalex.org/I2802827176"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly Shill","raw_affiliation_strings":["Barrow Neurological Institute Phoenix AZ United States","1Barrow Neurological Institute Phoenix AZ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Barrow Neurological Institute Phoenix AZ United States","institution_ids":["https://openalex.org/I1324766304"]},{"raw_affiliation_string":"1Barrow Neurological Institute Phoenix AZ United States","institution_ids":["https://openalex.org/I1324766304"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023953577","display_name":"Eric J. Pappert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135520","display_name":"Vale (Canada)","ror":"https://ror.org/045h8gy65","country_code":"CA","type":"company","lineage":["https://openalex.org/I165476936","https://openalex.org/I4210135520"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Eric Pappert","raw_affiliation_strings":["Cynapsus Therapeutics, Inc. Toronto ON Canada","2Cynapsus Therapeutics, Inc. Toronto ON Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":[]},{"raw_affiliation_string":"2Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":["https://openalex.org/I4210135520"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080534839","display_name":"Bruce Dzyngel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135520","display_name":"Vale (Canada)","ror":"https://ror.org/045h8gy65","country_code":"CA","type":"company","lineage":["https://openalex.org/I165476936","https://openalex.org/I4210135520"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Bruce Dzyngel","raw_affiliation_strings":["Cynapsus Therapeutics, Inc. Toronto ON Canada","2Cynapsus Therapeutics, Inc. Toronto ON Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":[]},{"raw_affiliation_string":"2Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":["https://openalex.org/I4210135520"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034230420","display_name":"Thierry Bilbault","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135520","display_name":"Vale (Canada)","ror":"https://ror.org/045h8gy65","country_code":"CA","type":"company","lineage":["https://openalex.org/I165476936","https://openalex.org/I4210135520"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Thierry Bilbault","raw_affiliation_strings":["Cynapsus Therapeutics, Inc. Toronto ON Canada","2Cynapsus Therapeutics, Inc. Toronto ON Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":[]},{"raw_affiliation_string":"2Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":["https://openalex.org/I4210135520"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059895493","display_name":"Albert Argo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135520","display_name":"Vale (Canada)","ror":"https://ror.org/045h8gy65","country_code":"CA","type":"company","lineage":["https://openalex.org/I165476936","https://openalex.org/I4210135520"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Albert Argo","raw_affiliation_strings":["Cynapsus Therapeutics, Inc. Toronto ON Canada","2Cynapsus Therapeutics, Inc. Toronto ON Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":[]},{"raw_affiliation_string":"2Cynapsus Therapeutics, Inc. Toronto ON Canada","institution_ids":["https://openalex.org/I4210135520"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4074,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.5984621,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"86","issue":"16_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.8769999742507935},{"id":"https://openalex.org/keywords/off-episodes","display_name":"OFF episodes","score":0.8090000152587891},{"id":"https://openalex.org/keywords/apomorphine","display_name":"apomorphine","score":0.9380000233650208},{"id":"https://openalex.org/keywords/sublingual-film","display_name":"sublingual film","score":0.7929999828338623},{"id":"https://openalex.org/keywords/oral-mucosa-drug-delivery","display_name":"oral mucosa drug delivery","score":0.8069999814033508},{"id":"https://openalex.org/keywords/disease-severity","display_name":"disease severity","score":0.5870000123977661},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":0.6129999756813049},{"id":"https://openalex.org/keywords/mds-updrs-part-iii","display_name":"MDS-UPDRS III","score":0.8730000257492065}],"concepts":[{"id":"https://openalex.org/C2777525119","wikidata":"https://www.wikidata.org/wiki/Q269111","display_name":"Apomorphine","level":4,"score":0.8857071399688721},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.7460190057754517},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.6944313645362854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6782050132751465},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3870640993118286},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2736026346683502},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.1049092710018158},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.10204735398292542}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.86.16_supplement.p2.336","doi":"https://doi.org/10.1212/wnl.86.16_supplement.p2.336","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.86.16_supplement.p2.336","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2467039515","https://openalex.org/W2343544248","https://openalex.org/W2496559268","https://openalex.org/W4230192949","https://openalex.org/W2804555981","https://openalex.org/W2227481404","https://openalex.org/W4254482893","https://openalex.org/W2789296631","https://openalex.org/W4389441081","https://openalex.org/W2226947214"],"abstract_inverted_index":{"Objectives:":[0],"APL-130277":[1,37,75,175],"is":[2],"a":[3,25,29,87,93],"sub-lingual":[4],"film":[5],"strip":[6],"designed":[7],"to":[8,92,120,183,197],"acutely":[9],"manage":[10],"Parkinson\u2019s":[11],"disease":[12,190],"(PD)":[13],"OFF":[14,43,54,62,71,119,139,153,182],"episodes":[15,44],"by":[16,136,207],"delivering":[17],"apomorphine":[18],"via":[19],"the":[20,34,39,70,112,155,181,184],"oral":[21],"mucosa.":[22],"We":[23],"present":[24],"subgroup":[26],"analysis":[27],"from":[28,118,180],"Phase":[30,192],"2":[31,58],"study":[32],"evaluating":[33,134],"effects":[35],"of":[36,42,60,95,106,138,145,147,152,157,189,203],"on":[38],"rapid":[40],"reversal":[41],"in":[45,69,82,99],"PD.":[46],"Methods:":[47],"PD":[48,148,178],"patients":[49,114,135,158,179],"with":[50,74,161],"at":[51],"least":[52],"one":[53],"episode/day":[55],"and":[56,103,127,150,166,201],">":[57],"hours":[59],"daily":[61],"time":[63],"were":[64,67,108,170],"included.":[65],"Patients":[66],"dosed":[68],"state,":[72],"starting":[73],"10":[76],"mg":[77,84],"and,":[78],"if":[79],"needed,":[80],"increased":[81],"5":[83],"increments":[85],"until":[86],"full":[88,121,185],"ON":[89,160,186],"was":[90],"achieved,":[91],"maximum":[94],"30":[96,125],"mg.":[97],"Change":[98],"MDS-UPDRS":[100,164,168],"Part":[101],"III":[102],"physician/patient":[104],"assessment":[105],"OFF/ON":[107],"evaluated.":[109],"Results:":[110],"Of":[111],"19":[113],"dosed,":[115],"15":[116,131],"converted":[117],"ON,":[122],"all":[123],"within":[124,130],"minutes":[126],"nearly":[128],"half":[129],"minutes.":[132],"When":[133],"number":[137,144],"episodes,":[140,154],"age,":[141],"levodopa":[142],"dose,":[143],"classes":[146],"medications":[149],"years":[151],"percentage":[156],"turning":[159],"APL-130277,":[162],"absolute":[163],"improvement":[165,169],"percent":[167],"similar":[171],"between":[172],"groups.":[173],"Conclusions:":[174],"rapidly":[176],"converts":[177],"state":[187],"regardless":[188],"severity.":[191],"3":[193],"studies":[194],"are":[195],"ongoing":[196],"further":[198],"evaluate":[199],"efficacy":[200],"safety":[202],"APL-130277.":[204],"Study":[205],"Supported":[206],"Cynapsus":[208],"Therapeutics,":[209],"Inc.":[210]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2531748673","counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-10-21T00:00:00"}
